55 related articles for article (PubMed ID: 18323794)
1. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.
Aiuti A; Biasco L; Scaramuzza S; Ferrua F; Cicalese MP; Baricordi C; Dionisio F; Calabria A; Giannelli S; Castiello MC; Bosticardo M; Evangelio C; Assanelli A; Casiraghi M; Di Nunzio S; Callegaro L; Benati C; Rizzardi P; Pellin D; Di Serio C; Schmidt M; Von Kalle C; Gardner J; Mehta N; Neduva V; Dow DJ; Galy A; Miniero R; Finocchi A; Metin A; Banerjee PP; Orange JS; Galimberti S; Valsecchi MG; Biffi A; Montini E; Villa A; Ciceri F; Roncarolo MG; Naldini L
Science; 2013 Aug; 341(6148):1233151. PubMed ID: 23845947
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of macrophage-specific promoters using lentiviral delivery in mice.
Levin MC; Lidberg U; Jirholt P; Adiels M; Wramstedt A; Gustafsson K; Greaves DR; Li S; Fazio S; Linton MF; Olofsson SO; Borén J; Gjertsson I
Gene Ther; 2012 Nov; 19(11):1041-7. PubMed ID: 22130447
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Labrosse R; Chu JI; Armant MA; Everett JK; Pellin D; Kareddy N; Frelinger AL; Henderson LA; O'Connell AE; Biswas A; Coenen-van der Spek J; Miggelbrink A; Fiorini C; Adhikari H; Berry CC; Cantu VA; Fong J; Jaroslavsky J; Karadeniz DF; Li QZ; Reddy S; Roche AM; Zhu C; Whangbo JS; Dansereau C; Mackinnon B; Morris E; Koo SM; London WB; Baris S; Ozen A; Karakoc-Aydiner E; Despotovic JM; Forbes Satter LR; Saitoh A; Aizawa Y; King A; Nguyen MAT; Vu VDU; Snapper SB; Galy A; Notarangelo LD; Bushman FD; Williams DA; Pai SY
Blood; 2023 Oct; 142(15):1281-1296. PubMed ID: 37478401
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for Wiskott-Aldrich syndrome: History, new vectors, future directions.
Ferrua F; Marangoni F; Aiuti A; Roncarolo MG
J Allergy Clin Immunol; 2020 Aug; 146(2):262-265. PubMed ID: 32623069
[No Abstract] [Full Text] [Related]
5. Erythroid lineage-specific lentiviral RNAi vectors suitable for molecular functional studies and therapeutic applications.
Bagchi A; Devaraju N; Chambayil K; Rajendiran V; Venkatesan V; Sayed N; Pai AA; Nath A; David E; Nakamura Y; Balasubramanian P; Srivastava A; Thangavel S; Mohankumar KM; Velayudhan SR
Sci Rep; 2022 Aug; 12(1):14033. PubMed ID: 35982069
[TBL] [Abstract][Full Text] [Related]
6. Induction of human blood group a antigen expression on mouse cells, using lentiviral gene transduction.
Fan X; Lang H; Zhou X; Zhang L; Yin R; Maciejko J; Giannitsos V; Motyka B; Medin JA; Platt JL; West LJ
Hum Gene Ther; 2010 Jul; 21(7):877-90. PubMed ID: 20163247
[TBL] [Abstract][Full Text] [Related]
7. A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.
Reichenbach P; Giordano Attianese GMP; Ouchen K; Cribioli E; Triboulet M; Ash S; Saillard M; Vuillefroy de Silly R; Coukos G; Irving M
Nat Biomed Eng; 2023 Sep; 7(9):1063-1080. PubMed ID: 37069267
[TBL] [Abstract][Full Text] [Related]
8. Physiological lentiviral vectors for the generation of improved CAR-T cells.
Tristán-Manzano M; Maldonado-Pérez N; Justicia-Lirio P; Muñoz P; Cortijo-Gutiérrez M; Pavlovic K; Jiménez-Moreno R; Nogueras S; Carmona MD; Sánchez-Hernández S; Aguilar-González A; Castella M; Juan M; Marañón C; Marchal JA; Benabdellah K; Herrera C; Martin F
Mol Ther Oncolytics; 2022 Jun; 25():335-349. PubMed ID: 35694446
[TBL] [Abstract][Full Text] [Related]
9.
Muñoz P; Tristán-Manzano M; Sánchez-Gilabert A; Santilli G; Galy A; Thrasher AJ; Martin F
Mol Ther Methods Clin Dev; 2020 Dec; 19():220-235. PubMed ID: 33102615
[TBL] [Abstract][Full Text] [Related]
10. The IS2 Element Improves Transcription Efficiency of Integration-Deficient Lentiviral Vector Episomes.
Sánchez-Hernández S; Gutierrez-Guerrero A; Martín-Guerra R; Cortijo-Gutierrez M; Tristán-Manzano M; Rodriguez-Perales S; Sanchez L; Garcia-Perez JL; Chato-Astrain J; Fernandez-Valades R; Carrillo-Galvez AB; Anderson P; Montes R; Real PJ; Martin F; Benabdellah K
Mol Ther Nucleic Acids; 2018 Dec; 13():16-28. PubMed ID: 30227274
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Functional Characterization of a Missense
Ahmad H; Requena T; Frejo L; Cobo M; Gallego-Martinez A; Martin F; Lopez-Escamez JA; Bronstein AM
Front Genet; 2018; 9():85. PubMed ID: 29628936
[TBL] [Abstract][Full Text] [Related]
12. Lent-On-Plus Lentiviral vectors for conditional expression in human stem cells.
Benabdellah K; Muñoz P; Cobo M; Gutierrez-Guerrero A; Sánchez-Hernández S; Garcia-Perez A; Anderson P; Carrillo-Gálvez AB; Toscano MG; Martin F
Sci Rep; 2016 Nov; 6():37289. PubMed ID: 27853296
[TBL] [Abstract][Full Text] [Related]
13. Use of zinc-finger nucleases to knock out the WAS gene in K562 cells: a human cellular model for Wiskott-Aldrich syndrome.
Toscano MG; Anderson P; Muñoz P; Lucena G; Cobo M; Benabdellah K; Gregory PD; Holmes MC; Martin F
Dis Model Mech; 2013 Mar; 6(2):544-54. PubMed ID: 23324327
[TBL] [Abstract][Full Text] [Related]
14. Specific marking of hESCs-derived hematopoietic lineage by WAS-promoter driven lentiviral vectors.
Muñoz P; Toscano MG; Real PJ; Benabdellah K; Cobo M; Bueno C; Ramos-Mejía V; Menendez P; Anderson P; Martín F
PLoS One; 2012; 7(6):e39091. PubMed ID: 22720040
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.
Astrakhan A; Sather BD; Ryu BY; Khim S; Singh S; Humblet-Baron S; Ochs HD; Miao CH; Rawlings DJ
Blood; 2012 May; 119(19):4395-407. PubMed ID: 22431569
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in lentiviral vector development and applications.
Mátrai J; Chuah MK; VandenDriessche T
Mol Ther; 2010 Mar; 18(3):477-90. PubMed ID: 20087315
[TBL] [Abstract][Full Text] [Related]
17. Wiskott-Aldrich Syndrome: Immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation.
Bouma G; Burns SO; Thrasher AJ
Immunobiology; 2009; 214(9-10):778-90. PubMed ID: 19628299
[TBL] [Abstract][Full Text] [Related]
18. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.
Marangoni F; Bosticardo M; Charrier S; Draghici E; Locci M; Scaramuzza S; Panaroni C; Ponzoni M; Sanvito F; Doglioni C; Liabeuf M; Gjata B; Montus M; Siminovitch K; Aiuti A; Naldini L; Dupré L; Roncarolo MG; Galy A; Villa A
Mol Ther; 2009 Jun; 17(6):1073-82. PubMed ID: 19259069
[TBL] [Abstract][Full Text] [Related]
19. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis.
Frecha C; Toscano MG; Costa C; Saez-Lara MJ; Cosset FL; Verhoeyen E; Martin F
Gene Ther; 2008 Jun; 15(12):930-41. PubMed ID: 18323794
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
